“Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s744. doi:10.25251/ppt8ep84.